Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.

Published in: The Annals of pharmacotherapy (2021)

CAB-RPV is the first complete long-acting injectable that provides a convenient way to maintain viral suppression with no negative effects on renal and bone health and few drug interactions.

Keyphrases

public health
healthcare
hyaluronic acid
sars cov
bone mineral density
antiretroviral therapy
tissue engineering
hiv infected patients
risk assessment
health promotion
bone regeneration